Literature DB >> 10408407

Minimal breast cancer: evaluation of histology and biological marker expression.

E A Dublin1, R R Millis, P Smith, L G Bobrow.   

Abstract

Ninety-eight minimal breast cancers (MBCs) diagnosed between 1975 and 1990, and all originally considered to be invasive were found, on review, to form three groups: (a) 28 predominantly invasive carcinomas < or = 10 mm ('predominant invasive'); (b) 48 predominantly ductal carcinoma in situ (DCIS) lesions with definite foci of invasion each < or = 10 mm ('predominant DCIS'); and (c) 22 DCIS without evidence of invasion ('pure DCIS'). Tumour histology and immunohistochemical expression of Ki-67, c-erbB2, p53, oestrogen receptor (ER), progesterone receptor (PR), and Bcl-2 were compared. The major finding was the contrasting features in the two invasive groups, with significant differences in their extent of invasion (P < 0.0001), tumour grade (P = 0.03), DCIS type (P = 0.008) and in marker expression. In the predominant invasive group, the infiltrative component was usually greater than 5 mm, low-grade and associated with well-differentiated DCIS. Expression of Ki-67, c-erbB2 and p53 was generally low, and that of ER, PR and Bcl-2 high. The predominant DCIS group in contrast had a much smaller, commonly high-grade, invasive component, usually with poorly differentiated DCIS and the reverse pattern of marker expression. Although not significant, survival of patients in the predominant invasive group was slightly better. These findings suggest that invasive MBCs should perhaps be treated as separate entities, in order to aid more appropriate selection of treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408407      PMCID: PMC2363109          DOI: 10.1038/sj.bjc.6690570

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Is radiotherapy as curative as mastectomy for patients with ductal carcinoma in situ?

Authors:  J R Harris; S J Schnitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

2.  Heterogeneity of intraductal carcinoma of the breast.

Authors:  A S Patchefsky; G F Schwartz; S D Finkelstein; A Prestipino; S E Sohn; J S Singer; S A Feig
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

3.  Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence.

Authors:  M D Lagios; F R Margolin; P R Westdahl; M R Rose
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

4.  Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy.

Authors:  D Rosner; W W Lane
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

5.  The concept of minimal breast cancer and the pathologist's role in the diagnosis of "early carcinoma".

Authors:  L V Ackerman; A L Katzenstein
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

Review 6.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

7.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

8.  Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression.

Authors:  P Querzoli; G Albonico; S Ferretti; R Rinaldi; D Beccati; S Corcione; M Indelli; I Nenci
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

9.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

Authors:  J Bartkova; D M Barnes; R R Millis; W J Gullick
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

10.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer.

Authors:  C Lovekin; I O Ellis; A Locker; J F Robertson; J Bell; R Nicholson; W J Gullick; C W Elston; R W Blamey
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

View more
  1 in total

Review 1.  Xenograft models of premalignant breast disease.

Authors:  F R Miller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.